Research Analysts Set Expectations for ARTL FY2024 Earnings

Artelo Biosciences, Inc. (NASDAQ:ARTL) – Equities researchers at HC Wainwright decreased their FY2024 earnings estimates for shares of Artelo Biosciences in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn ($2.62) per share for the year, down from their previous forecast of ($2.41). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Artelo Biosciences’ current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Artelo Biosciences’ Q4 2024 earnings at ($0.74) EPS and FY2025 earnings at ($1.61) EPS.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06.

Separately, EF Hutton Acquisition Co. I upgraded shares of Artelo Biosciences to a “strong-buy” rating in a research note on Tuesday, October 1st.

Artelo Biosciences Trading Down 9.0 %

Shares of NASDAQ ARTL opened at $1.11 on Monday. The firm has a market capitalization of $3.59 million, a price-to-earnings ratio of -0.39 and a beta of 1.35. Artelo Biosciences has a one year low of $1.00 and a one year high of $1.75. The business has a fifty day simple moving average of $1.15 and a 200 day simple moving average of $1.27.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.